Insider Transactions in Q3 2024 at Gilead Sciences, Inc. (GILD)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,246
-17.21%
|
$1,784,664
$84.5 P/Share
|
|
Sep 12
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+16.84%
|
$1,425,000
$57.92 P/Share
|
|
Sep 12
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
29,357
-14.74%
|
$2,436,631
$83.74 P/Share
|
|
Sep 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-1.46%
|
$24,867
$81.44 P/Share
|
|
Sep 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
639
+2.95%
|
-
|
|
Sep 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
292
-0.79%
|
$23,652
$81.44 P/Share
|
|
Sep 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
901
+2.39%
|
-
|
|
Sep 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,749
-0.95%
|
$384,669
$81.44 P/Share
|
|
Sep 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,295
+2.01%
|
-
|
|
Sep 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,766
-1.76%
|
$143,046
$81.44 P/Share
|
|
Sep 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,821
+3.67%
|
-
|
|
Sep 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,682
-1.2%
|
$136,242
$81.44 P/Share
|
|
Sep 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,641
+2.52%
|
-
|
|
Sep 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,734
-1.59%
|
$140,454
$81.44 P/Share
|
|
Sep 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,752
+3.32%
|
-
|
|
Aug 28
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
9,513
-8.27%
|
$742,014
$78.03 P/Share
|
|
Aug 13
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,490
-4.56%
|
$400,770
$73.98 P/Share
|
|
Aug 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
980
-2.65%
|
$71,540
$73.66 P/Share
|
|
Aug 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
3,678
+9.05%
|
-
|
|
Jul 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
8,744
+16.42%
|
-
|
|
Jul 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
2,917
-20.05%
|
$221,692
$76.51 P/Share
|
|
Jul 01
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.03%
|
$136,000
$68.63 P/Share
|